May 31, 2026 | ASCO 2026: Revolution Medicines Pancreatic Data Called 'Unprecedented'; Ivonescimab 34% OS episode artwork

EPISODE · Jun 1, 2026 · 11 MIN

May 31, 2026 | ASCO 2026: Revolution Medicines Pancreatic Data Called 'Unprecedented'; Ivonescimab 34% OS

from The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus · host BZ Group

RevMed's ASCO pancreatic cancer data earn 'unprecedented' from three major outlets — potential paradigm shift in a historically intractable tumor. Plus ivonescimab's 34% OS improvement with caveats,Pfizer-Innovent's $10.5B deal for 12 cancer programs, and GSK/Ionis's buried hepatitis B 'functional cure.'Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, RevolutionMedicines, ivonescimab, Akeso, Summit Therapeutics, Pfizer, Innovent Biologics,Eli Lilly, ASCO 2026, pancreatic cancer, KRAS, RAS, lung cancer, bepirovirsen,GSK, Ionis, hepatitis B, Braftovi, Lorbrena, Talzenna, Erleada, Zepbound,Foundayo, MannKind, Afrezza, Incyte, Monjuvi, DLBCL, BMS, Retevmo, Allogene,Lilly, Novo Nordisk, Merck, J&J

RevMed's ASCO pancreatic cancer data earn 'unprecedented' from three major outlets — potential paradigm shift in a historically intractable tumor. Plus ivonescimab's 34% OS improvement with caveats,Pfizer-Innovent's $10.5B deal for 12 cancer programs, and GSK/Ionis's buried hepatitis B 'functional cure.'Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, RevolutionMedicines, ivonescimab, Akeso, Summit Therapeutics, Pfizer, Innovent Biologics,Eli Lilly, ASCO 2026, pancreatic cancer, KRAS, RAS, lung cancer, bepirovirsen,GSK, Ionis, hepatitis B, Braftovi, Lorbrena, Talzenna, Erleada, Zepbound,Foundayo, MannKind, Afrezza, Incyte, Monjuvi, DLBCL, BMS, Retevmo, Allogene,Lilly, Novo Nordisk, Merck, J&J

NOW PLAYING

May 31, 2026 | ASCO 2026: Revolution Medicines Pancreatic Data Called 'Unprecedented'; Ivonescimab 34% OS

0:00 11:58

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus?

This episode is 11 minutes long.

When was this The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus episode published?

This episode was published on June 1, 2026.

What is this episode about?

RevMed's ASCO pancreatic cancer data earn 'unprecedented' from three major outlets — potential paradigm shift in a historically intractable tumor. Plus ivonescimab's 34% OS improvement with caveats,Pfizer-Innovent's $10.5B deal for 12 cancer...

Can I download this The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!